Compare PARK & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | FBIO |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 80.4M |
| IPO Year | 2025 | 2011 |
| Metric | PARK | FBIO |
|---|---|---|
| Price | $20.42 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 34.4K | ★ 261.4K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.40 |
| EPS | 0.16 | ★ 2.86 |
| Revenue | N/A | ★ $63,262,000.00 |
| Revenue This Year | $7.06 | $55.22 |
| Revenue Next Year | $6.17 | $40.55 |
| P/E Ratio | $123.56 | ★ $0.76 |
| Revenue Growth | N/A | ★ 9.69 |
| 52 Week Low | $12.29 | $2.17 |
| 52 Week High | $26.79 | $4.53 |
| Indicator | PARK | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 25.55 |
| Support Level | $19.29 | N/A |
| Resistance Level | $21.17 | $2.53 |
| Average True Range (ATR) | 1.02 | 0.09 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 55.34 | 4.12 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.